Abstract

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Author(s): Dib Jean G, Abdulmohsin Saud

Issue: Jan/Feb 2008 - Compounding for Hospice and Cancer Patients

Page(s): 8-14

Download in electronic PDF format for $75

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is used in the treatment of cancer. It was the first clinically available angiogenesis inhibitor in the U.S. Recently, bevacizumab has been used by ophthalmologists in the intravitreal treatment of choroidal neovascularization in agerelated macular degeneration. Since all published trials were less than one year in duration, including follow up, no conclusion can be drawn about the long-term safety and efficacy of intravitreal bevacizumab. In open-label studies, however, intravitreal bevacizumab has yielded marked improvements in visual acuity and central retinal thickness. Compounding pharmacists who are validated in aseptic compounding can prepare intravitreal bevacizumab from the available preservative-free phosphate-buffered intravenous solution using strict aseptic technique.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2008 Pg. 8-14	Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Author(s): Dib Jean G, Abdulmohsin Saud
Jan/Feb 2015 Pg. 70-72	Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr
Jul/Aug 2022 Pg. 330-335	Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes Author(s): Bartoll Aaron Puplà, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jan/Feb 2013 Pg. 74-85 View Sample	The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Sep/Oct 2014 Pg. 418-426	Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation Author(s): Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Jan/Feb 2017 Pg. 62	Infliximab 1% Ophthalmic Solution Author(s): Allen Loyd V Jr
Jul/Aug 2022 Pg. 336-341	Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops Author(s): Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2011 Pg. 302-307	Treating Inner Ear Disorders with Intratympanic Drug Administration Author(s): McElhiney Linda F
May/Jun 2012 Pg. 190-195	I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease Author(s): McElhiney Linda F
Nov/Dec 2009 Pg. 506-515	Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis Author(s): Mixon William, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2020 Pg. 515-518	Development and Evaluation of an Anti-aging Cosmetic Formulation Exploring Antioxidant Potential of Vitis vinifera L. Author(s): Carneiro Jaqueline, Marques Gonçalves Melissa, Vicente Pereira Airton
Sep/Oct 2016 Pg. 399-404	Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 495-500	Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments Author(s): Allen Loyd V Jr
Nov/Dec 2009 Pg. 540-543	Quality-Control Analytical Methods: Applications and Sterility of Autologous Eye Drops Author(s): Reed-Kane Dana, Carlson Rachel A, Kupiec Thomas C, Vu Nicole
Sep/Oct 2019 Pg. 418-421	Measurement of Free Iodine in Different Formulations of Povidone-Iodine Eye Drops 5% Author(s): Berisa Prado Silvia, Riestra Ayora Ana Cristina, Trelles Campa Adrián
Jul/Aug 2018 Pg. 268	PreScription: Factors Related to Drug Waste and Pharmacy Solutions Author(s): Allen Loyd V Jr
Sep/Oct 2010 Pg. 421	Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution Author(s): Allen Loyd V Jr
May/Jun 2011 Pg. 183-188	Home Infusion: Available Vascular Access Devices and Common Therapies Author(s): Kennedy Steve, Williams LaVonn A